Skip Navigation



Journal of the National Cancer Institute Advance Access published online on February 26, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/5/373    most recent
djn012v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Richardson, P. G.
Right arrow Articles by Bladé, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richardson, P. G.
Right arrow Articles by Bladé, J.
Related Collections
Right arrowArticle about this Correspondence
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival

Paul G. Richardson, Ruben Niesvizky, Kenneth C. Anderson, Joan Bladé

Affiliations of authors: Dana-Farber Cancer Institute, Boston, MA (PGR, KCA); Weill Medical College of Cornell University, New York Presbyterian Hospital, New York (RN); Hospital Clinic of Barcelona, Barcelona, Spain (JB)

Correspondence to: Paul G. Richardson, MD, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA 02115 (e-mail: paul_richardson@dfci.harvard.edu).

The first 10% of the full text of this article appears below.

Panageas et al. (1) recently showed that progression-free survival (PFS) is dependent on the assessment schedule; the same is true of time to progression (TTP). Other factors that may affect TTP include: 1) whether it is measured from diagnosis, randomization, or first dose; 2) whether progression is defined by investigator assessment or a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Article about this Correspondence

When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Katherine S. Panageas, Leah Ben-Porat, Maura N. Dickler, Paul B. Chapman, and Deborah Schrag
J Natl Cancer Inst 2007 99: 428-432. [Abstract] [Full Text] [PDF]

Related Article in JNCI

When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Katherine S. Panageas, Leah Ben-Porat, Maura N. Dickler, Paul B. Chapman, and Deborah Schrag
J Natl Cancer Inst 2007 99: 428-432. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NEJMHome page
J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al.
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N. Engl. J. Med., August 28, 2008; 359(9): 906 - 917.
[Abstract] [Full Text] [PDF]